Anti-RSV (Palivizumab), Humanized Antibody

• Data sheet: View or download

The research-grade biosimilar is a humanized IgG1 kappa monoclonal antibody that is produced by recombinant DNA technology. The antibody is used to prevent RSV infections. RSV is a non-segmented, enveloped, single-stranded, negative-sense virus that is known to cause mild lower respiratory tract infections in infants. The antibody specifically targets an epitope in the antigenic A site (between amino acids 258 and 275) of the RSV fusion glycoprotein and prevents the entry of the virus inside the host cell. The antibody is composed of 95% human and 5% murine antibody sequences. It is consists of two heavy chains and two light chains and has a molecular_weight of 148 kDa. The original drug received FDA approval to treat prophylaxis in children. It is also recommended to infants who are at high risk, either due to premature birth, or medical problems such as congenital heart disease and bronchopulmonary dysplasia (BPD).